FDA Drug · D-0007-2016

Vytorin (ezetimibe and simvastatin) tablets, 10 mg/20 mg, each tablet contains 10 mg ezetimibe and 20 mg simvastatin, Rx Only, 1000 count Bottle, Manuf. For Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ 08889, NDC 66582-0312-82.

Class II · Terminated

Presence of Foreign Tablet/Capsule: Vytorin 10 mg/40 mg tablets were found in bottles of Vytorin 10 mg/20 mg tablets.

Affected lots / codes — check yours against thisLot number: L013425, Exp. 11/2016

Recalling firm: Merck Sharp & Dohme, Wilson Facility, Wilson, NC
Classification: Class II (temporary or reversible harm possible)
Status: Terminated
Quantity: N/A
Distribution: KY, MS and OH.
Recall initiated: August 14, 2015
Classified: October 5, 2015
Terminated: May 4, 2016
Initiation: Voluntary: Firm initiated

Official source. This record is published by the U.S. FDA through the openFDA enforcement database. View the unmodified government record:
https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0007-2016%22

Important. Recalls target specific lots and codes — compare the affected lots above against your own product. This page reproduces public FDA data for readability; EveryRecall is independent and not affiliated with the FDA.

Check this brand across all 8 databases →